Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: A systematic review

International Journal of Antimicrobial Agents

Volumn 36, Issue 2, 2010, Pages 106-110

  Kocher, S ^a   Muller W ^a   Resch, B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Gram positive bacteria; Linezolid; Nosocomial infection; Preterm infant

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANEMIA; AREA UNDER THE CURVE; DATA BASE; DIARRHEA; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; IATROGENIC DISEASE; LOOSE FECES; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PREMATURITY; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RED MAN SYNDROME; SHORT SURVEY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; VOMITING;

ACETAMIDES; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INJECTIONS, INTRAVENOUS; OXAZOLIDINONES; UNITED STATES;

EID: 77953808292     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.030     Document Type: Short Survey

References (32)

1. Sohn A.H., Garret D.O., Sinkowitz-Cochran R.L., Grohskopf L.A., Levine G.L., Stover B.H., et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr 2001, 139:821-827.
2. Brodie S.B., Sands K.E., Gray J.E., Parker R.A., Goldmann D.A., Davis R.B., et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J 2000, 19:56-65.
3. Stoll B.J., Gordon T., Korones S.B., Shankaran S., Tyson J.E., Bauer C.R., et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996, 129:72-80.
4. Stoll B.J., Gordon T., Korones S.B., Shankaran S., Tyson J.E., Bauer C.R., et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996, 129:63-71.
5. Slee A.M., Wuonola M.A., McRipley R.J., Zajac I., Zawada M.J., Bartholomew P.T., et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987, 31:1791-1797.
6. Wise R., Andrews J.M., Boswell F.J., Ashby J.P. The in vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998, 42:721-728.
7. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
8. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003, 138:135-142.
9. Stevens D.L., Dotter B., Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004, 2:51-59.
10. Breha-Millet J., Calvet L., Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents 2003, 22:28-34.
11. Wallace R.J., Brown-Elliot B.A., Ward S.C., Crist C.J., Mann L.B., Wilson R.W. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45:764-767.
12. Sweeney M.T., Zurenko G.E. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci and selected Gram-negative organisms. Antimicrob Agents Chemother 2003, 47:1902-1906.
13. Kloss P., Xiong L., Shinabarger D.L., Mankin A.S. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999, 294:93-101.
14. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
15. Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2002.
16. Kearns G.L., Jungbluth G.L., Abdel-Rahman S.M., Hopkins N.K., Welshman I.R., Grzebyk R.P., et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003, 74:413-422.
17. Kaplan S.L., Deville J.G., Yogev R., Morfin M.R., Wu E., Adler S., et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003, 22:677-685.
18. Deville J.G., Adler S., Azimi P.H., Jantausch B.A., Morfin M.R., Beltran S., et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatr Infect Dis J 2003, 22(9 Suppl.):S158-S163.
19. Meissner H.C., Townsend T., Wenman W., Kaplan S.L., Morfin M.R., Edge-Padbury B., et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003, 22(9 Suppl.):S186-S192.
20. Graham P.L., Ampofo K., Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002, 21:798-799.
21. Kumar S., Kohlhoff S., Valencia G., Hammerschlag M.R., Sharma R. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents 2007, 29:740-741.
22. Langgartner M., Mutenthaler A., Haiden N., Pollak A., Berger A. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008, 93:F397.
23. Ang J.Y., Luna J.L., Turner D.R., Asmar B.I. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003, 22:1101-1102.
24. Sung T.J., Kim H.M., Kim M.J. Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid. Clin Pediatr (Phila) 2008, 47:504-506.
25. Groll A.H., Hoehn R., Schaefer V., Bauer K., Schloesser R.L. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents 2006, 27:256-258.
26. Klingkowski U., Huth R.G., Habermehl P., Knuf M. Linezolid in two premature babies with necrotizing enterocolitis and infection with vancomycin-resistant Enterococcus. Klin Padiatr 2004, 216:21-23. [in German].
27. Ng P.C., Chow V.C., Lee C.H., Ling J.M., Wong H.L., Chan R.C. Persistent Staphylococcus capitis septicemia in a preterm infant. Pediatr Infect Dis J 2006, 25:652-654.
28. Jungbluth G.L., Welshman I.R., Hopkins N.K., Bruss J.B., Wu E., Kearns G.L. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants. Pediatr Res 2002, 51:464A. [Abstract no. 2712].
29. Kearns G.L., Abdel-Rahman S.M., Blumer J.L., Reed M.D., James L.P., Jacobs R.F., et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000, 19:1178-1184. [Erratum. Pediatr Infect Dis J 2001;20:732].
30. Leeder J.S., Kearns G.L. Pharmacogenetics in paediatrics. Implications for practice. Pediatr Clin North Am 1997, 44:55-77.
31. Biedenbach D.J., Jones R.N. Disk diffusion test interpretative criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. J Clin Microbiol 1997, 35:3198-3202.
32. Hachem R., Afif C., Gokaslan Z., Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001, 20:432-434.